Ultrasound and Magnetic Resonance Imaging for Assessing Muscle Contractile Performance in FSHD - An Exploratory Study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Facioscapulohumeral dystrophy (FSHD) is one of the most common hereditary neuromuscular disorders (NMD), with an estimated prevalence of 2000 patients in the Netherlands. Magnetic resonance imaging (MRI) and muscle ultrasound have contributed to an enhanced understanding of the pathophysiology of Facioscapulohumeral Muscular Dystrophy (FSHD). Previously, our group demonstrated the potential presence of an intermediate factor between muscle fiber loss and clinical weakness in FSHD. The influence of disrupted muscle architecture in FSHD on muscle contractile efficiency is a likely candidate for this factor, and remains relatively unexplored. In this study, we aim to assess the use of ultrasound-defined contractile performance, in comparison with current measures including structural MRI, for monitoring disease progression in FSHD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:

• Age between 18 and 70 years.

• Informed consent is given by the participant.

• Ability to read and understand written and spoken instruction in Dutch.

• Willingness and ability to understand nature and content of the study

Locations
Other Locations
Netherlands
Radboud university medical center
RECRUITING
Nijmegen
Contact Information
Primary
Odette Van Iersel, MSc
Odette.vaniersel@radboudumc.nl
0243611111
Backup
Jonne Doorduin, PhD
Jonne.Doorduin@radboudumc.nl
0243611111
Time Frame
Start Date: 2024-04-10
Estimated Completion Date: 2027-01-31
Participants
Target number of participants: 100
Treatments
Healthy individuals
Healthy individuals between 18 and 70 years old.
Patients with FSHD
Individuals with clinically and genetically proven FSHD type 1 or type 2.
Sponsors
Leads: Radboud University Medical Center
Collaborators: Solve FSHD

This content was sourced from clinicaltrials.gov